Click (NASDAQ:CLIK) Stock Price Down 2.7% – What’s Next?

Click Holdings Limited (NASDAQ:CLIK) was down 2.7% on Monday . The company traded as low as $1.41 and last traded at $1.44. Approximately 325,145 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 4,478,592 shares. The stock had previously closed at $1.48.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Click currently has an average rating of “Sell”.

Click Trading Up 4.3%

The stock’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $4.21.

Click (NASDAQ:CLIK) last released its earnings results on Monday, May 11th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $3.79 million during the quarter.

Institutional Investors Weigh In On Click

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click as of its most recent filing with the Securities and Exchange Commission (SEC).

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.